JP Morgan Chase’s Entellus Medical, Inc. Common Stock ENTL Stock Holding History

JP Morgan Chase’s Portfolio ENTL Stock Details ENTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-22,572	Closed	-$551K	–	5795
2017 Q4	$551K	Buy	22,572 +13,103	+138%	+$252K	﹤0.01%	4023
2017 Q3	$168K	Buy	9,469 +5,605	+145%	+$97.1K	﹤0.01%	4154
2017 Q2	$64K	Buy	+3,864	New	+$53.8K	﹤0.01%	4301
2017 Q1	–	Sell	-10,403	Closed	-$197K	–	5362
2016 Q4	$197K	Buy	+10,403	New	+$200K	﹤0.01%	4188

JP Morgan Chase's ENTL Position: Q1 2018 in Review

JP Morgan Chase sold out of Entellus Medical, Inc. Common Stock (ENTL) in Q1 2018, closing a stake of 22,572 shares — an estimated $551K sold.

JP Morgan Chase first reported a position in ENTL in Q4 2016 and held it in 4 quarters. The position peaked at $551K in Q4 2017. 0 funds tracked by Wall St. Rank hold ENTL as of Q1 2018.

JP Morgan Chase reported no remaining Entellus Medical, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
JP Morgan Chase sold 22,572 Entellus Medical, Inc. Common Stock shares in Q1 2018, an estimated $551K.
JP Morgan Chase first reported a position in Entellus Medical, Inc. Common Stock in Q4 2016 and held it in 4 quarters.
JP Morgan Chase's Entellus Medical, Inc. Common Stock position peaked at $551K in Q4 2017.
0 funds tracked by Wall St. Rank held Entellus Medical, Inc. Common Stock as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.